Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
GPC3
REST API REST API
Homo sapiens
GPC3 is differentially expressed in 195 experiments: 137 organism parts: liver, lung, ... (135 more);, 117 disease states: normal, lung adenocarcinoma, ... (115 more);, 55 cell types 204 cell lines 23 compound treatments and 65 other conditions.
Synonyms SGBS, OCI-5, SDYS, SGB, DGSX, SGBS1
Orthologs Q3ZBZ6_BOVIN (Bos taurus)   gpc3 (Danio rerio)   Gpc3 (Rattus norvegicus)   Gpc3 (Mus musculus)   F1N8X1_CHICK (Gallus gallus)   dally (Drosophila melanogaster)   A9ULF4_XENTR (Xenopus laevis)   GPC3 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, protein binding, negative regulation of cell proliferation, extracellular space, negative regulation of smoothened signaling pathway, membrane, lysosome, proteinaceous extracellular matrix, positive regulation of BMP signaling pathway, anchored to plasma membrane, extracellular region, heparan sulfate proteoglycan binding, anchored to membrane, anterior/posterior axis specification, negative regulation of growth, anatomical structure morphogenesis, integral to plasma membrane, positive regulation of smoothened signaling pathway, positive regulation of endocytosis, negative regulation of epithelial cell proliferation, organ morphogenesis, regulation of growth, coronary vasculature development, peptidyl-dipeptidase inhibitor activity, kidney development, bone mineralization, branching involved in ureteric bud morphogenesis, embryonic hindlimb morphogenesis, positive regulation of protein catabolic process, body morphogenesis, positive regulation of glucose import, lung development, mesonephric duct morphogenesis, cell proliferation involved in kidney development, negative regulation of canonical Wnt receptor signaling pathway, osteoclast differentiation, cell proliferation involved in metanephros development, positive regulation of Wnt receptor signaling pathway, planar cell polarity pathway
InterPro Term Glypican
UniProt Accession C9JLE3, B1AJP6, P51654
Gene-Disease Assocation WILMS TUMOR 1; WT1, SIMPSON-GOLABI-BEHMEL SYNDROME, TYPE 1; SGBS1
Search EB-eye ENSG00000147257
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-17189, E-GEOD-22541, E-GEOD-6573, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-1880, E-GEOD-14464, E-GEOD-19639, E-GEOD-2450, ... (23 experiments)

Factor Value U/D Experiments
MDA-MB-231
2
E-TABM-420, E-MTAB-62
647V
1
E-MTAB-37
SKMEL1
1
E-MTAB-37
PC3
1
E-GEOD-14464
EB2
1
E-MTAB-37
BFTC905
1
E-MTAB-37
198 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-360, E-GEOD-20677, E-MEXP-466, ... (28 experiments)

Factor Value U/D Experiments
human embryonic stem cell
2
E-GEOD-18265, E-GEOD-18147
n/a
1
E-MTAB-24
naive T cell
1
E-GEOD-1460
culture-derived megakaryocytes
1
E-MEXP-70
epithelial cell
1
E-GEOD-4483
cardiac myocyte
1
E-AFMX-5
49 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-MEXP-2069, E-GEOD-2549, E-TABM-15, ... (42 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
1
3
E-MTAB-37, E-GEOD-2514, E-MTAB-62, E-MEXP-231
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-995
hepatocellular carcinoma
2
E-MTAB-62, E-MTAB-37
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
myxoid liposarcoma
2
E-MTAB-62, E-GEOD-6481
small cell lung cancer
1
E-MTAB-62
111 more value(s).


Compound treatment

studied in E-GEOD-1615, E-MEXP-1269, E-GEOD-5258, E-GEOD-3284, E-GEOD-6907, ... (12 experiments)

Factor Value U/D Experiments
none
6
E-GEOD-5824, E-GEOD-412, E-TABM-868, E-GEOD-7307, E-GEOD-1615, ... (6 experiments)
estradiol
1
E-GEOD-20081
Cxcl12
1
E-GEOD-7307
cadmium chloride 2.5-hydrate
1
E-GEOD-6907
phenol
1
E-GEOD-6907
unknown
1
E-GEOD-7307
17 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-860, E-MEXP-1251, ... (10 experiments)

Clinical treatment
studied in E-GEOD-6532

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-GEOD-6236, E-GEOD-2666, ... (8 experiments)

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-22544, E-GEOD-3325, E-TABM-147, E-GEOD-19665 ... (5 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578

Genotype
studied in E-TABM-1029, E-GEOD-3494, E-GEOD-21750, E-TABM-321, E-TABM-601, ... (6 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1446, E-MEXP-1273

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-GEOD-1926, E-GEOD-19519, E-GEOD-6919, E-GEOD-10433, ... (22 experiments)

Injury
studied in E-GEOD-19743

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-AFMX-1, E-GEOD-426

Organism status
studied in E-GEOD-19188

Phenotype
studied in E-GEOD-21750, E-GEOD-1657

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

Qpcr egfr dct
studied in E-GEOD-5851

Qrt pcr areg dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-17204

RNAi
studied in E-GEOD-1676, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70

Sex
studied in E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Treatment
studied in E-GEOD-19246, E-GEOD-15799

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-1561, E-GEOD-4922

Tumor size
studied in E-GEOD-3494

Processing time: 0.356 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM